Cat FIP: New Antiviral Treatments and Welfare Outcomes

Feline infectious peritonitis has been transformed from a uniformly fatal disease to a treatable condition by antiviral drugs, dramatically improving welfare outcomes for affected cats.

Key Facts

FIP is caused by a mutated form of feline coronavirus and was historically uniformly fatal
GS-441524 and related antivirals have achieved remission rates exceeding 85% in clinical trials
Treatment requires 12 weeks of daily antiviral administration followed by monitoring for relapse
Both effusive (wet) and non-effusive (dry) forms, including neurological FIP, respond to antivirals
Early diagnosis and rapid treatment initiation are associated with better outcomes
Cost of treatment has fallen substantially as generic formulations became available in many regions

Welfare Considerations

The transformation of FIP from a death sentence to a treatable disease represents one of the most significant welfare advances in veterinary medicine in recent years. Cats previously humanely euthanized within days or weeks of diagnosis can now achieve full clinical remission and live normal lifespans. Treatment does involve daily medication for 12 weeks which has some burden, but the welfare benefit of survival and recovery far outweighs the treatment burden for most cats. Access to treatment remains an equity issue in some regions.

What You Can Do

Seek immediate veterinary assessment and FIP testing if your cat shows signs including fever, weight loss, and fluid accumulation
Ask your vet about antiviral treatment options and current availability in your region
Connect with FIP owner support communities for guidance on accessing treatment
Advocate for regulatory approval of FIP antivirals in jurisdictions where they remain unlicensed
Support research into FIP coronavirus biology to improve diagnostic tools and treatment protocols